Skip to main navigation Skip to search Skip to main content

Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)

  • M. Alsina
  • , A. Varga
  • , A. Amatu
  • , J. H.M. Schellens
  • , P. O. Witteveen
  • , V. Boni
  • , V. Moreno
  • , K. Bol
  • , A. Lourbakos
  • , M. Magin Ferrer
  • , E. Wasserman

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)viii223-viii224
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
Publication statusPublished - 1 Oct 2018

Cite this